PerkinElmer debuts dried blood spot-based COVID-19 serology test

By staff writers

July 22, 2020 -- PerkinElmer has introduced a dry blood spot-based serology test for SARS-CoV-2 immunoglobulin G (IgG) antibodies using its genetic screening processor (GSP)/dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) platforms.

Up to 5,000 samples of the fully automated kit can be processed per day, according to the company. PerkinElmer said that the finger-prick sample collection devices enable both decentralized sample collection and high-throughput testing.

In Europe, the kit is being marketed as a CE-IVD test. The firm plans to apply for an emergency use authorization with the U.S. Food and Drug Administration.

PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.
PerkinElmer says it's not target of federal probe
PerkinElmer on May 18 said that while the company had received subpoenas from federal investigators looking into healthcare fraud at medical labs, the...
PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.
PerkinElmer gets regulatory nod in U.S. for coronavirus test
PerkinElmer is among the latest vendors to receive an emergency use authorization from the U.S. Food and Drug Administration for a reverse transcription...
PerkinElmer adjusts Q1 2020 revenue down
PerkinElmer announced that it anticipates its first quarter 2020 revenue to be lower than previously expected.

Copyright © 2020

Last Updated ls 7/22/2020 2:06:10 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current